| References: |
Description of Oprozomib (ONX 0912): ONX 0912 is an orally bioavailable proteasome inhibitor with potential antineoplastic activity. ONX 0912 inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally per Formed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of Oprozomib (ONX-0912) in water, the solubility of Oprozomib (ONX-0912) in DMSO, the solubility of Oprozomib (ONX-0912) in PBS buffer, the animal experiment（test） of Oprozomib (ONX-0912),the in vivo,in vitro and clinical trial test of Oprozomib (ONX-0912),the cell experiment（test） of Oprozomib (ONX-0912),the IC50, EC50 and Affinity of Oprozomib (ONX-0912), please contact DC Chemicals. |
-chemical-structure.gif)
